---
type: "Topics"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/topics/38819266.md"
description: "What you said is true, I'll just add two points:1. The weight-loss drug market is a blue ocean with demand exceeding supply. Eli Lilly's production capacity cannot swallow the entire market, and the high entry barriers make it difficult for new manufacturers to enter.2. Novo Nordisk's semaglutide has FDA-approved cardiovascular prevention and kidney disease delay effects, which is why federal Medicare and other national health insurance plans can cover it.$Novo Nordisk AS(NVO.US)"
datetime: "2026-02-22T06:54:59.000Z"
locales:
  - [en](https://longbridge.com/en/topics/38819266.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/38819266.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/38819266.md)
author: "[艾萨克·牛顿](https://longbridge.com/zh-HK/profiles/15057684.md)"
---

> 支持的語言: [English](https://longbridge.com/en/topics/38819266.md) | [简体中文](https://longbridge.com/zh-CN/topics/38819266.md)


# What you said is true, I'll just add two points:1.…


### 相關股票

- [Novo Nordisk AS (NVO.US)](https://longbridge.com/zh-HK/quote/NVO.US.md)
- [Eli Lilly (LLY.US)](https://longbridge.com/zh-HK/quote/LLY.US.md)